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A collection of recent Nature papers examines the relationship between endothelial precursors and hemato-
poietic cells. Two of these studies (Eilken et al., 2009; Lancrin et al., 2009) use time-lapse imaging with live
markers and genetic analysis of differentiating ESCs to reveal that even non-aortic-derived endothelial cells
are hemogenic.The tight association of hematopoietic
cells and blood vessel endothelia, as
seen in yolk sac blood islands, has long
suggested a developmental relationship
between the two lineages, leading to the
proposal of a common progenitor, the he-
mangioblast. AVEGF-R2-positiveprogen-
itor, capable of differentiating into either
endothelial or hematopoietic cells de-
pending on the growth factors in the
culture medium, can indeed be isolated
from the caudal mesoderm of the gastru-
lating avian embryo (Eichmann et al.,
1997), mouse embryo (Huber et al.,
2004), or murine embryonic stem cells
(ESCs) (Choi et al., 1998). An alternative
theory is that hematopoietic cells originate
from a specific type of endothelium desig-
nated as hemogenic. Indeed, transient,
time-specific, hemogenesis arising at the
floor of aortic endothelium is prominent in
embryos of many vertebrate species.
An elegant study recently delineated
in vivo the hemogenic potential of the
mouseembryoaorta, vitelline, andumbilical
arteries, hereafter collectively designated
as aorta (Zovein et al., 2008). Transgenic
animals carrying an inducible VE-cadherin
Cre gene were crossed with a ROSA26R
Cre reporter line. Ashort pulseof tamoxifen,
delivered at the stage of ‘‘AGM’’ hemogen-
esis, induced CRE, labeling permanently
only the endothelium present at this time
and its progeny. As development pro-
gressed, abundant labeled hematopoietic
cells were detected in the fetal liver, the
bone marrow, and the thymus. Long-term
multilineage blood cell production, an
essential hallmark of HSCs, is thus an attri-
bute of cells derived from the aortic endo-
thelium. The mouse line created by these
authors offers a powerful tool to study the
involvement of different developmental
stages of endothelium in the emergence of
HSCs. Given that hematopoiesis occurssequentially in different embryonic sites, it
will be interesting to see this transgenic
system used again to target the endothe-
lium at different periods and thus assess
other putative sites of hemogenesis.
Two current Nature articles take an
in vitro approach to examine the emer-
genceofhematopoieticcells fromendothe-
lial populations derived from ESC cultures.
One reports a fine-tuned, continuous live
analysis of hematopoietic production from
a hemogenic intermediate over time (Eilken
et al., 2009). In this study, the authors use
a sorted-out population of VEGF-R2+ and
E-cadherin ESC-derived cells that arise
after 4 days in differentiation conditions,
and cultured them on OP9 stromal cells.
Single-cell progeny was followed by time-
lapse microscopy. The changes in molec-
ular markers, monitored on the living cells,
strikingly correlated with the evolution of
the cells from an adherent endothelial
morphology to a nonadherent blood cell
morphology (Figure 1).
In the second study, a similar population
of ESC-derived hemangioblasts gave rise
to ‘‘blastcolonies’’ after36–48hrcomprised
of both endothelial and a few hematopoi-
esis-committed (CD41+) cells (Lancrin
et al., 2009).Over time, the latter population
became predominant in the culture and
began expressing CD45. The switch from
the tight adherent (endothelial) to the
detached (hematopoietic) phenotype, visu-
alized through time-lapse photography,
corresponded with the evolution of flow
cytometry profiles observed in parallel
(Figure 1). ESCs deficient in the transcrip-
tion factors SCL, required for both primitive
and definitive hemopoiesis, or Runx1,
dispensable for primitive hematopoiesis
but necessary for definitive hemopoiesis,
were also examined. Production of CD41+
cells from Runx1/ ESCs was drastically
reduced, though clusters of adherent cellsCell Stem Cand a few blast colonies did appear.
However, if a doxycycline-inducible Runx1
construct was inserted in the mutant cells,
CD41+ cells were generated upon induc-
tion. In contrast, SCL/ ESCs assayed in
this system resulted in the total absence of
eitherblast or adherent colonies. Thus there
appear to be two discrete stages of differ-
entiation downstream of the hemangio-
blast: SCL-dependent Tie2+/c-Kit+/CD41
‘‘tight’’ colonies and CD41+ blast colonies
that require Runx1.
Thus, the Eilken study dissects the live
progress of hemogenic endothelial cells,
whereas the Lancrin results delineate
some of the molecular features of the
cellular intermediates and also define
and dissociate two closely knit stages in
the process. In both studies, the authors
confirmed their findings by culturing cells
isolated from yolk sac-containing gastru-
lating embryos, supporting the conclusion
that hemogenesis requires an endothelial
transition.
Consistent with the model and results
described above, a third Nature paper
(Chen et al., 2009) recently reported that
Runx1 activity in VE-cadherin-expressing
cells is required for a brief, discrete period
for the emergence of HSCs from endothe-
lium, andyetRunx1becomesdispensable
after their progeny commit to hematopoi-
esis. Interestingly, this paper disclosed
that the vast majority of adult blood cells
was derived from cells that expressed
VE-Cad during their life history, thus con-
firming the data presented by Zovein
et al. (2008).
Putting all of the recent studies together
brings us to make a series of comments.
First, although hematopoiesis appears
required, as indicated by the molecular
constraints, to passage through an endo-
thelial stage, this transition is cytologically
prominent only in the aorta andassociatedell 4, March 6, 2009 ª2009 Elsevier Inc. 189
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PreviewsFigure 1. Two In Vitro Models of Hemogenic Endothelium
The model according to Eilken et al. (2009) is presented above the central time line. ESC-derived Flk1+/
E-cadherin cells were seeded onOP9 stromal cells. Antigen expression was followed on living cells using
a gene tracer (Claudin5-Venus fusion gene controlled by VE-Cad regulatory elements; and fluorescent
probes for AcLDL-DiI, CD41, and CD45). The model according to Lancrin et al. (2009) is presented below
the central time line. Embryoid body-derived cells were seeded on gelatin in liquid medium supplemented
with cytokines. The molecular phenotypes were analyzed by flow cytometry at different time points. The
hemogenic endothelium stage was materialized by the SCL/ and Runx1/ arrests. In both cases, the
endothelial markers disappeared while the hematopoietic markers appeared and increased.arteries. Also, while the concept of ‘‘he-
mogenic endothelium’’ was coined based
on histological observations within the
aorta, the data discussed here and else-
where (for review, see Yoshimoto et al.,
2008) seem to indicate that definitive
hematopoiesis in the yolk sac also derives
from a hemogenic endothelium. Second,
it is important to recall that while the
hierarchy of blood cells has been worked
out in the murine system, paving the way
for human cell studies, hematopoietic
ancestor-progeny relationships were first
established in the avian model (Eichmann
et al., 1997; Jaffredo et al., 1998), which
is uniquely effective in lineage-tracing
studies. Finally, it was in avian studies
that the distinction between nonhemo-
genic (dorsal) and hemogenic (ventral)190 Cell Stem Cell 4, March 6, 2009 ª2009 Eendothelia was established (Pardanaud
et al., 1996). Indeed, an important chal-
lenge facing the field is to dissect the
molecular constraints responsible for
limiting the blood-forming potential of
distinct endothelial cells. Of note, accord-
ing to Eilken et al. (2009), only 1 in 3000
ESC-derived colonies is hemogenic.
In addition to informing the immediate
field of developmental hematopoiesis,
one might ask whether it is important to
dissect the process of HSC emergence
with such fine-tuned precision. Indeed it
is, in part because the transcription factors
required during the earliest stages of
hematopoietic lineage maturation (SCL,
Runx1, Vav) have all been implicated in
various types of leukemia. In addition,
from a historical perspective, blood celllsevier Inc.studies have defined many of the
concepts and techniques that have since
been applied across the field of stem cell
research, and thus decoding the early
stages of commitment will likely also
advance the field of cell therapy. In partic-
ular, a critical—yet unanswered—issue
concerns the developmental program
that determines the point past which
stem cells, hematopoietic or otherwise,
can no longer be produced. The recently
described in vivo models appear poised
to reveal essential details about this
important point. At the same time, the
in vitro explorations disclose the cellular
steps and molecular combinations
involved in the emergence of a population
of cells that are central to promoting stem
cell therapy and cancer treatments.
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